AJ-VACCINES
22.4.2020 08:10:11 CEST | Business Wire | Pressemeddelelse
På trods af en igangværende indsats for at udrydde polio, har der været en stigning af registrerede poliotilfælde fra 2018 til 2019. Fremadrettet vil AJ Vaccines ’ antigen reducerende teknologi give mulighed for at udvide udbuddet af poliovaccine, med potentiale for at levere op til 100 millioner doser i femårsperioden 2020-2024, hvilket vil dække den uopfyldte globale efterspørgsel på inaktiverede poliovacciner.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20200421005974/da/
En milepælspræstation
Udviklingen af den første dosis reducerede enkelt-komponent inaktiverede poliovaccine er en milepæl for den betydelige investering og innovation, der er foretaget i den danske vaccineproduktion. ”WHO's prækvalifikation er en anerkendelse af vores fortsatte investeringer, som gør det muligt for AJ Vaccines at imødekomme den stigende efterspørgsel på effektive poliovacciner, og vi åbner hermed et nyt kapitel i virksomhedens fortsatte rejse mod at bistå den danske befolkning og et stigende antal mennesker globalt” , siger Mr. Abdulaziz Hamad Aljomaih, hovedinvestor i AJ Vaccines.
En hyldest til dedikerede medarbejdere
Opnåelsen af WHO-prækvalifikationen er en hyldest til medarbejderne for deres engagement og deres bidrag, som har involveret en omfattende gennemgang af produktionsprocesser og kvalitetskontrolprocedurer, uafhængig laboratorietestning, vurdering af filer samt en inspektion af produktionsfaciliteter, der er udført i fællesskab mellem WHO og Lægemiddelstyrelsen i 2019. ”Prækvalifikationen er en anerkendelse af vores engagerede medarbejderes kompetencer og ligger i forlængelse af vores virksomheds vision, der stræber efter en verden fri for alvorlige sygdomme på tværs af generationer” , siger dr. Tabassum Khan, formand for AJ Vaccines.
Betydelige investeringer
Picovax®-udviklingsprojektet er støttet af Bill & Melinda Gates Foundation. ”Siden vores overtagelse af AJ Vaccines i 2017 har vi investeret markant i den strategiske udvidelse af vores produktionsfaciliteter og rekrutteret 200 nye medarbejdere for at sikre AJ Vaccines’ position som en betydelig aktør på vaccinemarkedet, der bidrager til det vigtige strategiske globale mål om at udrydde polio” , siger Jesper Helmuth Larsen, administrerende direktør i AJ Vaccines.
Den nye vaccine vil spille en afgørende rolle for The Global Polio Eradication Initiative (GPEI)
Den nye inaktiverede poliovaccine (IPV) er indikeret til aktiv immunisering mod poliomyelitis ved primær vaccination hos spædbørn fra seks uger og til revaccination af spædbørn, børn og unge. En antigen reduceret IPV giver beskyttelse, der kan sammenlignes med den, der opnås ved andre inaktiverede poliovacciner, der i øjeblikket er tilgængelige. ”Den antigen reducerende teknologi sikrer en tiltrængt forøgelse i udbuddet og vil bidrage til at imødekomme det stigende behov for inaktiveret poliovacciner, der støtter The Global Polio Eradication Initiative” , afslutter Jérôme Cabannes, COO AJ Vaccines.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200421005974/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum